Highlights
- •Alemtuzumab has been associated with stroke and cervicocephalic dissections.
- •Monitoring blood pressure is currently recommended by the EMA.
- •Monitoring blood pressure is not useful in predicting these rare side effects.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Spontaneous multiple cervical artery dissections after alemtuzumab.Mult. Scler. J. 2019;
- Intracerebral hemorrhage during alemtuzumab administration.Lancet Neurol. 2019; 18: 329-331
US FDA. FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab) [Accessed 13 May; 2019]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-serious-risks-stroke-and-blood-vessel-wall-tears-multiple-sclerosis-drug.
EMA. Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing [Accessed 13 May 2019]. Available from: https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-referral-use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review_en.pdf.
- Clinically insignificant effect of alemtuzumab infusions on vital signs: a prospective observational study in patients with relapsing-remitting multiple sclerosis.Int. J. MS Care. 2019;
Article info
Publication history
Published online: September 25, 2019
Accepted:
September 25,
2019
Received in revised form:
September 23,
2019
Received:
July 19,
2019
Identification
Copyright
© 2019 Elsevier B.V. All rights reserved.
